Renown cancer researcher and biotech veteran brings expertise in developing novel cancer therapeutics in emerging biotech companies
Boston, Mass. — Revere Pharmaceuticals, an emerging biopharmaceutical company developing small molecule drugs targeting the Ras-homologous (Rho) family GTPases, announced today that in connection with Revere’s Asset and Purchase Agreement with Geneyus, Marc Lippman, MD, MACP, FRCP has joined its Board of Directors. Dr. Lippman, a world renown cancer researcher and professor in the departments of oncology and medicine at Georgetown University Medical Center, co-Founded Geneyus in 20xx. Dr. Lippman also bring a wealth of experience building emerging biotech companies having served on the Board of Directors of Seattle Genetics since 2000.
“We are thrilled and fortunate to have Marc join our Board of Directors,” says Bob Silverman, CEO of Revere. “As an exceptional world-class scientist and clinician with over 20 years of experience as a director of a major biotech company, Marc brings important depth and breadth to our company.”
“Rac1 is an underappreciated oncology target,” said Dr. Lippman. “I launched Geneyus based on the potential of Rac1 inhibition to address the unmet needs of many distinct cancer patient populations, and I look forward to working with the Revere team to realize the promise of targeting these important molecular switches.”
Dr. Marc Lippman is a recognized leader in breast cancer research and is currently professor in the departments of oncology and medicine at Georgetown University Medical Center. He has served as director of the Georgetown Lombardi Comprehensive Cancer Center. An accomplished researcher, Dr. Lippman is widely known for his work in the investigation and treatment of breast cancer, and he previously led the medical breast cancer section of the medicine branch at the National Cancer Institute. Throughout his career, Lippman has garnered many honors including a Clinical Investigator Award from the American Federation for Clinical Research, the Transatlantic Medal and Lecture from the British Endocrine Societies, the Astwood Award from the Endocrine Society, the Bernard Fisher Award from the University of Pittsburgh, the Rosenthal Award from the American Association for Cancer Research, and the Brinker Award for Basic Science from the Komen Foundation.
Dr. Lippman is author of many chapters and books, including a textbook on breast disease. He has also published over 400 peer-reviewed articles and is editor-in-chief of Breast Cancer Research and Treatment.
About Revere Pharmaceuticals
Revere Pharmaceuticals is a biopharmaceutical company developing small molecule drugs targeting the Ras-homologous (Rho) family GTPases, molecular switches that are central to cancer progression and other disease processes. Based on a deep understanding of how to balance the active and inactive forms of the GTPase, the company has built a pipeline of novel small molecules that target Rac1, select Rac1 variants and CDC42. The company is headquartered in Boston, Massachusetts. For more information, please visit www.reverepharma.com.